SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study. [electronic resource]
Producer: 20141118Description: 303-4 p. digitalISSN:- 1665-2681
- Antiviral Agents -- therapeutic use
- Cohort Studies
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- genetics
- Hepatitis C -- blood
- Humans
- Interferon-alpha -- therapeutic use
- International Cooperation
- Male
- Middle Aged
- Polyethylene Glycols -- therapeutic use
- Pragmatic Clinical Trials as Topic
- RNA, Viral -- blood
- Recombinant Proteins -- therapeutic use
- Ribavirin -- therapeutic use
- Treatment Outcome
- Viral Load
No physical items for this record
Publication Type: Letter; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.